March 3, 2026Open Access

Janus kinase inhibitors therapy in idiopathic inflammatory myopathies: a case series

Puntos clave

Patients treated with JAK inhibitors showed clinical improvement, particularly in interstitial lung disease.
JAKi treatment demonstrated a notable steroid-sparing effect, enhancing patient management options.
Observational analysis of refractory idiopathic inflammatory myopathies used JAK inhibitors to assess effectiveness and safety.
Future studies are necessary to confirm the results and expand understanding of JAK inhibitors' role in therapy.

Resumen

JAKi therapy appears to be clinically effective, well tolerated, and safe in patients with refractory IIM, with a particular benefit in ILD. The steroid sparing effect was also a major outcome. Future prospective and controlled studies are warranted to confirm these preliminary results and better define the therapeutic potential of JAKi in IIM.

Me gusta

Guardar

Ver artículo completo